CREATE
TRANSFORMATIVE
MEDICINES
TRANSFORMATIVE
MEDICINES
A global leader in innovative solutions for the discovery, development, and manufacture of novel nanoparticle medicines.
Every Stage
of Development
of Development
Announcing Daiichi Sankyoa Precision NanoSystems' Newest Clinical Client
Daiichi Sankyoa has signed a license agreement for use of the NanoAssemblr GMP System configuring a customized microfluidics-based GMP System that is fit-for-purpose and stage appropriate. Daiichi Sankyo is a customer of PNI using the NanoAssemblr suite of instruments including the Benchtop and the Blaze to perform research and development to create innovative medicines to address unmet medical needs. Read more...
With over 280 systems placed worldwide, PNI's proprietary microfluidics technology, the NanoAssemblr platform is the industry leader platform used by over 95 pharma/biotech and 90 academic customers in the areas of gene and cell therapy, cancer, rare diseases, and infectious diseases.
Finding trusted partners in the journey from discovery to clinical manufacturing becomes as critical as the journey itself. PNI is uniquely positioned to offer the flexibility needed to move products from the clinical development stages through to commercial scale in a nimble and agile manner, accelerating the research and drug development process.
We provide a wide range of expertise in formulation and clinical solutions, a proprietary platform and reagents.
Thousands of compounds may be potential candidates for development as a medical treatment. Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations. Nanomedicine is playing a key role in pharmaceutical discovery, largely in the form of nanoparticle-based delivery systems for drugs.
After early testing, only a small number of compounds look promising and call for further study. In this stage, optimizing a wide range of nanomedicine formulations with the NanoAssemblr® Benchtop or
the Blaze™
depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Develop nanoparticle drugs for clinical evaluation and to support clinical development for their commercialization. Scalable manufacturing is a significant challenge to making revolutionary medicine and Formulation Solutions is ready to assist you in your nanoparticle manufacturing process development. PNI provides a custom Clinical Solution for development and commercial supply.
Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Technology
Our technology provides a seamless path forward to larger experimental studies, all the way to the clinic: low volume prototype formulations are easily scaled-up using larger instruments of the NanoAssemblr® family, which provides microfluidic mixing and manufacturing of nanoparticles.
Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine.
over
70%
of top pharmaceutical companies work with PNI
200+
instruments are installed
worldwide
80+
biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine
drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly
in the drug development process. Contact our Business Development Team.
PNI Feature in BioWorld
"As we bite off different problems and succeed on those, we can leverage those technologies," CEO Taylor explains. "We like to think that we're democratizing and lowering the barrier for people to get into these important technologies."
Evonik Collaboration
PNI announces a manufacturing collaboration agreement with Evonik for the tech transfer of the NanoAssemblr® system to Evonik Canada for late-stage clinical research.
License Agreement with Entos Pharmaceuticals
Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines.
Upcoming Events See All
July
21 - 24
2019
Controlled Release Society (CRS)
We invite you to join us in Valencia, Spain for the 46th Controlled Release Society Annual Meeting & Exposition! Held in the Palacio de Congresos de València from July 21st-24th, this premier event sports a powerful lineup of presenters including Nobel Laureates, Acade...
September
09 - 10
2019
American DDF Summit
Held in Boston, American DDF Summit brings innovative solutions to the greatest challenges in pharmaceutical development. Covering both small molecules and biologics, you’ll be able find new technologies,concepts and case studies in areas such as formulation design for po...
September
22 - 24
2019
NanoDDS
Hosted at the Massachusetts University of Technology, NanoDDS highlights new groundbreaking discoveries and developments in nanomedicine and drug delivery. Revolutionary advances in this area require collaboration among researchers working in a diverse array of fields including ...
Resource Center
Publication - Summary
April 04, 2019
The Journal of Neuroscience
PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease
Read MorePublication - Summary
February 07, 2019
Nano Research
Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...
Read MoreApplication Note
January 16, 2019
mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials
Read More
Publication - Summary
September 24, 2018
Nucleic Acid Therapeutics
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Read MorePoster
July 01, 2018
Publication - Summary
February 27, 2018
Cell Reports
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
Read MoreStay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
MENU
